In a BRAF‐mutated melanoma, this T‐cell response could be amplified, by broadening the TCR repertoire at baseline (BRAF/MEK inhibitors) and by subsequently increasing the number of proliferating CD4+ T cells (checkpoint inhibitors), thus improving the likelihood of a positive ICI therapy response. The gene discussed is MAP2K7; the disease is melanoma.